BioPharma Resources

Drug Trial Radar · NCT06215716

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,650

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Feb 2033

Study completion Feb 2033

Sponsor

Lead sponsor
Akero Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Conditions

  • NASH With Fibrosis
  • MASH With Fibrosis

Interventions

  • EfruxiferminDrug

    Administered by subcutaneous injection

  • PlaceboDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosisTime frame: 52 Weeks
  2. Event-free survivalTime frame: 240 Weeks

Locations

361 sites in 18 countries. Site status is shown where the registry gives one.

  • Akero Clinical Study Site

    Birmingham, Alabama · Recruiting

  • Akero Clinical Study Site

    Dothan, Alabama · Recruiting

  • Akero Clinical Study Site

    Chandler, Arizona · Recruiting

  • Akero Clinical Study Site

    Flagstaff, Arizona · Completed

  • Akero Clinical Study Site

    Peoria, Arizona · Recruiting

  • Akero Clinical Study Site

    Tucson, Arizona · Recruiting

  • Akero Clinical Study Site

    Tucson, Arizona · Recruiting

  • Akero Clinical Study Site

    Tucson, Arizona · Recruiting

  • Akero Clinical Study Site

    Tucson, Arizona · Recruiting

  • Akero Clinical Study Site

    Conway, Arkansas · Completed

  • Akero Clinical Study Site

    Jonesboro, Arkansas · Completed

  • Akero Clinical Study Site

    Little Rock, Arkansas · Recruiting

  • Akero Clinical Study Site

    North Little Rock, Arkansas · Recruiting

  • Akero Clinical Study Site

    Chula Vista, California · Completed

  • Akero Clinical Study Site

    Coronado, California · Recruiting

  • Akero Clinical Study Site

    Escondido, California · Recruiting

  • Akero Clinical Study Site

    Folsom, California · Recruiting

  • Akero Clinical Study Site

    Inglewood, California · Completed

  • Akero Clinical Study Site

    La Mesa, California · Completed

  • Akero Clinical Study Site

    Lancaster, California · Completed

  • Akero Clinical Study Site

    Lancaster, California · Recruiting

  • Akero Clinical Study Site

    Long Beach, California · Recruiting

  • Akero Clinical Study Site

    Los Angeles, California · Completed

  • Akero Clinical Study Site

    Los Angeles, California · Recruiting

  • Akero Clinical Study Site

    Los Angeles, California · Recruiting

  • Akero Clinical Study Site

    Newport Beach, California · Recruiting

  • Akero Clinical Study Site

    Orange, California · Recruiting

  • Akero Clinical Study Site

    Palm Springs, California · Completed

  • Akero Clinical Study Site

    Pasadena, California · Recruiting

  • Akero Clinical Study Site

    Redwood City, California · Recruiting

  • Akero Clinical Study Site

    Sacramento, California · Recruiting

  • Akero Clinical Study Site

    San Diego, California · Completed

  • Akero Clinical Study Site

    San Diego, California · Completed

  • Akero Clinical Study Site

    San Diego, California · Recruiting

  • Akero Clinical Study Site

    San Francisco, California · Recruiting

  • Akero Clinical Study Site

    San Francisco, California · Recruiting

  • Akero Clinical Study Site

    Santa Maria, California · Recruiting

  • Akero Clinical Study Site

    Aurora, Colorado · Recruiting

  • Akero Clinical Study Site

    Colorado Springs, Colorado · Recruiting

  • Akero Clinical Study Site

    Englewood, Colorado · Recruiting

Showing 40 of 361 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.